Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models

Journal of Medicinal Chemistry

Volumn 45, Issue 2, 2002, Pages 333-343

  Huang, Xaioqin ^a,b   Xu, Liaosa ^c   Luo, Xiaomin ^a   Fan, Kangnian ^c   Ji, Ruyun ^a   Pei, Gang ^b   Chen, Kaixian ^a   Jiang, Hualiang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 2 HYDROXYL 4 PHENYLBUTANOIC ACID DERIVATIVE; KYNOSTATIN 272; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; COMPUTER PREDICTION; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DIAGNOSTIC ACCURACY; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; GEOMETRY; HYDROGEN BOND; INHIBITION KINETICS; LIGAND BINDING; MATHEMATICAL MODEL; MOLECULAR INTERACTION; NONHUMAN; PRACTICE GUIDELINE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY ANALYSIS;

ALGORITHMS; HIV PROTEASE INHIBITORS; HIV-1; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENYLBUTYRATES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037122679     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0102710     Document Type: Article

References (53)

1. A structural model for the retroviral proteases
2. Complete nucleotide sequence of the AIDS virus, HTLV-III
3. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A
4. Crystal structures of HIV-1 protease-inhibitors complexes
5. Active human immunodeficiency virus protease is required for viral infectivity
6. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation
7. Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: Effects of fluoro substitution
8. Macromolecular inhibitors of HIV-1 protease
9. Analysis of the s3 and s3′ subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitors efficacious against FIV, SIV, and HIV in vitro and ex vivo
10. The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease
11. Methodology for protein-ligand binding studies: Appilication to a model for drug resistance, the HIV/FIV protease system
12. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: The effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters
13. Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs
14. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA
15. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA?II. Modification of pyrrolidine ring at P1′ proline
16. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site
17. Structure-activity relationship of HIV-1 protease inhibitors containing α-hydroxy-β-amino acids. Detailed study of P1 site
18. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease
19. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor sdz283-910: Agreement of time-resolved spectroscopy and molecular dynamics simulations
20. Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors
21. Molecular modeling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human a-thrombin
22. Comparative molecular field analysis. 1. Effect of shape on binding of steroids to carrier proteins
23. Molecular similarity indices in a comparative analysis(CoMSIA) of drug molecules to correlate and predict their biological activity
24. Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor
25. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analogue containing allophenylnorstatine
26. Automated docking using Lamarckian genetic algorithm and empirical binding free energy function
27. Minimization by random search techniques
28. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4
29. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases
30. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1′ phenyl substituents: X-ray crystal structure assisted design
31. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: Comparisons with molecular modeling
32. Molecular clusters of π-systems: Theoretical studies of structures, spectra, and origin of interaction energies
33. A Method for two-electron Gaussian integral and integral derivative evaluation using recurrence relations
34. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions
35. 2 symmetric inhibitor complexed to HIV-1 protease
36. Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors
37. Flexibility and function in HIV-1 protease
38. Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease
39. Multivariate data analysis and experimental design in biomedical research
40. Kynostatin (kni)-227 and -272, highly potent anti-HIV agents: Conformationally constrained inhiboitors of HIV protease containing allophenorstatine
41. Molecular mechanisms of resistance: Free energy calculations of mutation effects on inhibitor binding to HIV-1 protease
42. Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease
43. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor
44. Free energy calculations: Applications to chemical and biochemical phenomena
45. Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations